Journal of Pediatric Neurology 2015; 13(02): 074-077
DOI: 10.1055/s-0035-1556768
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Neurodevelopmental Outcomes in Children with Down Syndrome and Infantile Spasms

Sarah Tapp
1   Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States
,
Tovi Anderson
1   Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States
,
Jeannie Visootsak
1   Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States
› Institutsangaben
Weitere Informationen

Publikationsverlauf

22. November 2014

29. Dezember 2014

Publikationsdatum:
07. August 2015 (online)

Preview

Abstract

Down syndrome (DS) is the most common genetic cause of intellectual disability in the United States. The prevalence of seizure in individuals with DS is 1 to 13%, and infantile spasm (IS) occurs in 6 to 32% of those with seizures. Since IS is relatively common in children with DS, it is important to understand the impact IS has on the neurodevelopmental outcomes to provide appropriate anticipatory guidance to help maximize the potential of these children. Our study is the first to compare the neurodevelopmental outcomes of children with DS and IS (DS + IS) to children with DS and no history of seizures (DS − IS). Using the Bayley scales of infant and Toddler development III, we assessed the neurodevelopment of 29 subjects (8 DS + IS and 21 DS − IS). Neurodevelopmental outcome was poor in the DS + IS cohort, but the delay in treatment does not appear to contribute to any differences in their developmental scores. However, when compared with children with DS − IS, the DS + IS cohort scored approximately 20 points less in all domains including cognitive, motor, and language (p < 0.05). Our results indicate that IS may impact the neurodevelopmental outcomes of children with DS + IS; thus, it is important to provide ongoing developmental and educational assessments and potentially additional therapies for children with DS + IS.